Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the Alethia brand; rapid immunoassays, a single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
Phone513-271-3700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$213.57 million
Profitability
Miscellaneous
Employees585
Next Earnings Date11/7/2019 (Confirmed)
OptionableOptionable
Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions
What is Meridian Bioscience's stock symbol?
Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."
How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?
Meridian Bioscience announced a quarterly dividend on Friday, January 25th. Shareholders of record on Monday, February 4th will be given a dividend of $0.125 per share on Thursday, February 14th. This represents a $0.50 annualized dividend and a yield of 4.98%. The ex-dividend date is Friday, February 1st. View Meridian Bioscience's Dividend History.
How were Meridian Bioscience's earnings last quarter?
Meridian Bioscience, Inc. (NASDAQ:VIVO) released its quarterly earnings results on Tuesday, July, 30th. The company reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.06. The firm earned $48.40 million during the quarter, compared to analyst estimates of $49.81 million. Meridian Bioscience had a net margin of 12.65% and a return on equity of 17.82%. The company's quarterly revenue was down 6.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.18 earnings per share. View Meridian Bioscience's Earnings History.
When is Meridian Bioscience's next earnings date?
How can I listen to Meridian Bioscience's earnings call?
Meridian Bioscience will be holding an earnings conference call on Thursday, November 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Meridian Bioscience issued on next quarter's earnings?
Meridian Bioscience updated its FY19 earnings guidance on Tuesday, July, 30th. The company provided EPS guidance of $0.63-0.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.56.
What price target have analysts set for VIVO?
3 brokers have issued 1-year price objectives for Meridian Bioscience's shares. Their predictions range from $9.00 to $14.00. On average, they expect Meridian Bioscience's stock price to reach $11.33 in the next year. This suggests a possible upside of 12.9% from the stock's current price. View Analyst Price Targets for Meridian Bioscience.
What is the consensus analysts' recommendation for Meridian Bioscience?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Meridian Bioscience.
What are Wall Street analysts saying about Meridian Bioscience stock?
Here are some recent quotes from research analysts about Meridian Bioscience stock:
- 1. Canaccord Genuity analysts commented, "We reiterate our SELL rating and $9 PT on VIVO. Third straight miss. FQ3/19 revs of $48.4M (-6% Y/Y) missed our/Street’s prior $49.8M (-4%), driven by broad-based weakness. Diagnostics declined 9% (vs. our -6%) driven by a ~21% decline in molecular ~15% decline in gastrointestinal revs (volume declines in 13% decline in H. Pylori revs due to price erosion). Life Science revs declined 0.3% due to softness in the 9% decline in molecular reagents. (-350bps) missed our 59%E. Meridian manufactured" an EPS beat based on lower investment and lower commissions paid to sales reps who missed their numbers. Adj. EPS of $0.16 beat our $0.07/Street’s $0.09. Third straight guide down." (7/31/2019)
- 2. According to Zacks Investment Research, "Meridian Bioscience, Inc. is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Its products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections. In addition, the company develops and manufactures a variety of biological and non-biological materials used in proficiency testing programs. Meridian diagnostic products are used outside of the human body and require little or no special equipment. Meridian Bioscience designs their products to enhance the well-being of the patient-while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis. " (7/5/2019)
Has Meridian Bioscience been receiving favorable news coverage?
News coverage about VIVO stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Meridian Bioscience earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Meridian Bioscience.
Are investors shorting Meridian Bioscience?
Meridian Bioscience saw a decline in short interest during the month of September. As of September 15th, there was short interest totalling 2,570,000 shares, a decline of 6.9% from the August 15th total of 2,760,000 shares. Based on an average daily volume of 285,000 shares, the short-interest ratio is presently 9.0 days. Approximately 6.1% of the shares of the stock are sold short. View Meridian Bioscience's Current Options Chain.
Who are some of Meridian Bioscience's key competitors?
Some companies that are related to Meridian Bioscience include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), Quidel (QDEL), Merit Medical Systems (MMSI), Atrion (ATRI), STAAR Surgical (STAA), Anika Therapeutics (ANIK), Cerus (CERS), Antares Pharma (ATRS) and OraSure Technologies (OSUR).
What other stocks do shareholders of Meridian Bioscience own?
Who are Meridian Bioscience's key executives?
Meridian Bioscience's management team includes the folowing people:
- Mr. John P. Kenny, CEO, Exec. VP of Diagnostics Bus. Unit & Director (Age 50)
- Ms. Susan D. Rolih, Consultant (Age 70)
- Ms. Melissa A. Lueke, Consultant (Age 56)
- Mr. Eric S. Rasmussen, Exec. VP & CFO (Age 51)
- Mr. Bryan Baldasare, Chief Accounting Officer, Sr. VP, Corp. Controller & Treasurer
Who are Meridian Bioscience's major shareholders?
Meridian Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.80%), Nisa Investment Advisors LLC (0.10%), Bowling Portfolio Management LLC (0.09%), State of Alaska Department of Revenue (0.08%) and Pacer Advisors Inc. (0.03%). Company insiders that own Meridian Bioscience stock include David Phillips, Dwight E Ellingwood, James M Anderson, John Mccune Jr Rice, John Mcilwraith, John P Kenny and Lawrence Baldini. View Institutional Ownership Trends for Meridian Bioscience.
Which major investors are selling Meridian Bioscience stock?
Which major investors are buying Meridian Bioscience stock?
VIVO stock was bought by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, State of Alaska Department of Revenue, Nisa Investment Advisors LLC and Pacer Advisors Inc.. Company insiders that have bought Meridian Bioscience stock in the last two years include David Phillips, Dwight E Ellingwood, James M Anderson, John Mccune Jr Rice, John Mcilwraith and John P Kenny. View Insider Buying and Selling for Meridian Bioscience.
How do I buy shares of Meridian Bioscience?
Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Meridian Bioscience's stock price today?
One share of VIVO stock can currently be purchased for approximately $10.04.
How big of a company is Meridian Bioscience?
Meridian Bioscience has a market capitalization of $428.81 million and generates $213.57 million in revenue each year. The company earns $23.84 million in net income (profit) each year or $0.74 on an earnings per share basis. Meridian Bioscience employs 585 workers across the globe.View Additional Information About Meridian Bioscience.
What is Meridian Bioscience's official website?
How can I contact Meridian Bioscience?
Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.
MarketBeat Community Rating for Meridian Bioscience (NASDAQ VIVO)
MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
